Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sudin Cold is an over-the-counter (OTC) combination pharmaceutical product developed and marketed by Group Pharmaceutical. It is formulated as an anti-cold tablet intended for the symptomatic relief of the common cold, influenza, and allergic rhinitis. The medication typically contains a combination of three active ingredients: paracetamol (acetaminophen), phenylephrine hydrochloride, and chlorpheniramine maleate. Paracetamol serves as an analgesic and antipyretic by inhibiting prostaglandin synthesis in the central nervous system. Phenylephrine acts as a nasal decongestant through selective alpha-1 adrenergic receptor agonism, leading to vasoconstriction in the nasal passages. Chlorpheniramine maleate is a first-generation antihistamine that antagonizes H1 receptors to alleviate symptoms such as sneezing, rhinorrhea, and itchy/watery eyes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sudin Cold.